Nutri Genomics Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 07-01-2025
- Paid Up Capital ₹ 0.10 M
as on 07-01-2025
- Company Age 12 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 7.90%
(FY 2022)
- Profit 3.98%
(FY 2022)
- Ebitda 80.15%
(FY 2022)
- Net Worth 90.92%
(FY 2022)
- Total Assets 35.39%
(FY 2022)
About Nutri Genomics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Suresh Nair, Sreekumar Nair, and Lekha Nair serve as directors at the Company.
- CIN/LLPIN
U74900KL2012PTC030636
- Company No.
030636
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Feb 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Nutri Genomics Private Limited offer?
Nutri Genomics Private Limited offers a wide range of products and services, including Research and Development (R&D) Work, Product Development Research.
Who are the key members and board of directors at Nutri Genomics?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suresh Nair  | Director | 29-Feb-2012 | Current |
| Sreekumar Nair | Director | 29-Feb-2012 | Current |
| Lekha Nair | Director | 29-Feb-2012 | Current |
Financial Performance of Nutri Genomics.
Nutri Genomics Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 7.9% increase. The company also saw a slight improvement in profitability, with a 3.98% increase in profit. The company's net worth Soared by an impressive increase of 90.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nutri Genomics?
In 2020, Nutri Genomics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bhadreswar Wellness And Healthcare Private LimitedActive 1 year 6 monthsSreekumar Nair is a mutual person
- Dr.Sree & Family Holdings Private LimitedActive 1 year 15 days
Sreekumar Nair and Lekha Nair are mutual person
- Biowell Functional Hospital Private LimitedActive 2 years 6 months
Sreekumar Nair and Lekha Nair are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nutri Genomics?
Unlock and access historical data on people associated with Nutri Genomics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nutri Genomics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nutri Genomics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
